BHCM
GYRE icon

Brevan Howard Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Brevan Howard Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.2K Buy
+13,808
New +$107K ﹤0.01% 2030

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brevan Howard Capital Management's GYRE Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Gyre Therapeutics (GYRE) in Q1 2026: 13,808 shares worth $96.2K. The stake represents ﹤0.01% of the portfolio and ranks #2030 among its holdings.

56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Brevan Howard Capital Management held 13,808 shares of Gyre Therapeutics worth $96.2K as of Q1 2026.
  • Gyre Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • Gyre Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2030 holding.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.